Fibre

Fibre is a London-based biotechnology company developing a platform for "programmable medicines" that target the gut microbiome. The company's technology focuses on "programmable fiber," using a proprietary diagnostic and computational engine to design precision prebiotic blends that optimize the production of short-chain fatty acids (SCFAs) based on an individual's unique microbiome profile. Fibre aims to treat chronic conditions such as Type 2 diabetes, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD) through these targeted interventions. The company is currently conducting clinical trials in collaboration with the NHS to validate the efficacy of its precision fiber therapeutics.